En desarrollo
Business·21.06.2026Resumen IA
US-China Biotech Deals Face Complications Amid Investment Restrictions
Cross-border biotech deals between China and the US are facing increased complexity and potential slowdown due to US restrictions on investment and technology transfers, according to analysts. Despite challenges, innovation from China is expected to drive continued partnerships, with out-licensing agreements projected to reach $240 billion.
S
SCMP Economy